Tag: Therapeutics
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Invest… –...
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of...
ALDX Stock News: Shareholders with Significant Losses in Aldeyra Therapeutics, I…...
SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of...
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging...
Cohort 1 patients exhibited a significant immune response consistent with the mechanism of actionSafety Review Committee approved continuation to the next cohort of...
BioXcel Therapeutics, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check,…...
RADNOR, Pa., Aug. 8, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class...
Aldeyra Therapeutics, Inc. (ALDX) Shareholder Notice: Robbins LLP Reminds Shareh… –...
SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of...
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages BioXcel Therapeutics, Inc. Inv…...
NEW YORK, July 28, 2023 /PRNewswire/ --WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics,...
Cessation Therapeutics Announces Food and Drug Administration Authorization for … –...
Company expects to initiate trial in August of 2023 CSX-1004 is being developed for prevention of fentanyl overdose, which claimed more than 74,000...
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recen…...
WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. AQST, (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines...
BTAI INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Notifies BioXcel Therapeutics,...
NEW YORK, July 22, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed...
ENB Therapeutics Presents Top-line Results from Phase 1b ENBOLDEN-101 Study in...
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor - a novel immune checkpoint
The ENB-003 in combination...